Work

EXPAND-1, a phase I/II study with ANV600, a novel PD-1 targeted IL-2R-βγ agonist, in monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors.

Year: 2025

Type: article

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.tps2701

Authors: Iphigenie Korakis, Martina Imbimbo, Emiliano Calvo, Sebastian Ochsenreither, Ignacio Ortego, Pascale Tomasini, Kaïssa Ouali, Alexander Desuki, Daniela Di Blasi, Eduard Gasal, Markus Joerger

Institutions: Institut universitaire du cancer de Toulouse Oncopole, Istituto Oncologico della Svizzera Italiana, Humboldt-Universität zu Berlin, Charité - Universitätsmedizin Berlin, Clinica Universidad de Navarra, Hôpital de la Timone, Institut Gustave Roussy, University Medical Center of the Johannes Gutenberg University Mainz, Kantonsspital St. Gallen

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410811544

FWCI:

Cites:

Cited by:

Related to: 10